{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:13:55Z","timestamp":1790633635839,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Popul Health Metrics"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Gastric cancer has historically been driven by long\u2011standing\n                      <jats:italic>Helicobacter pylori<\/jats:italic>\n                      infection. The nationwide expansion of\n                      <jats:italic>H. pylori<\/jats:italic>\n                      eradication therapy beginning in 2013 created a unique opportunity to evaluate its population\u2011level impact on gastric cancer mortality. However, short\u2011term mortality trends following eradication are difficult to interpret because they reflect overlapping influences of ageing, cohort replacement, and cumulative infection history. This study aimed to provide a model\u2011based, population\u2011level assessment of the early impact of eradication during the first decade of nationwide implementation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We applied a two\u2011layer analytic framework consisting of a counterfactual analysis comparing observed mortality during 2013\u20132021 with expected mortality had eradication uptake remained at pre\u20112013 levels, combined with a structured state\u2011transition (Markov) model with time\u2011dependent parameters. To estimate annual gastric cancer deaths prevented and the proportion of mortality reduction attributable to eradication, the model integrated age\u2011specific biological hazard, cumulative infection history, cohort\u2011specific\n                      <jats:italic>H. pylori<\/jats:italic>\n                      prevalence, and annual changes in eradication uptake.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Observed gastric cancer deaths declined from 48,632 in 2013 to 41,624 in 2021, whereas counterfactual gastric cancer deaths declined more modestly, from 49,779 to 49,453. The divergence between observed and counterfactual deaths steadily widened from 1,147 in 2013 to 7,829 in 2021. Model\u2011based estimates indicated that eradication prevented 6,461 gastric cancer deaths during 2013\u20132021, with annual deaths prevented increasing from 165 in 2015 to 1,604 in 2021, particularly among adults aged 60\u201379, who showed the most pronounced early benefit reflecting cumulative infection history and real-world uptake patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The early population\u2011level impact of\n                      <jats:italic>H. pylori<\/jats:italic>\n                      eradication is consistent with a 16% reduction in gastric cancer deaths by 2021. These findings provide real\u2011world insight into how primary prevention can shape short\u2011term national cancer trends. This approach offers a quantitative framework to inform future prevention strategies in high\u2011prevalence settings seeking to evaluate early implementation effects.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12963-026-00487-0","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T01:05:48Z","timestamp":1779671148000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Early population-level impact of Helicobacter pylori eradication on gastric cancer mortality in Japan: a counterfactual analysis of short-term divergence"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5200-4300","authenticated-orcid":false,"given":"Akiko","family":"Kowada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"487_CR1","unstructured":"Cancer Information Service, National Cancer Center, Japan. Cancer registry and statistics. Available at: https:\/\/ganjoho.jp\/reg_stat\/statistics\/stat\/cancer\/5_stomach.html. Accessed January 30, 2026."},{"key":"487_CR2","unstructured":"IARC Working Group. Population-based Helicobacter pylori screen-and-treat strategies for gastric cancer prevention: guidance on implementation. In: Park JY, editor. IARC Working Group Report No. 12. Lyon. France: International Agency for Research on Cancer; 2025."},{"key":"487_CR3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/j.1523-5378.2011.00889.x","volume":"16","author":"T Matsuo","year":"2011","unstructured":"Matsuo T, Ito M, Takata S, et al. Low prevalence of Helicobacter pylori-negative gastric cancer among Japanese. Helicobacter. 2011;16:415\u20139. https:\/\/doi.org\/10.1111\/j.1523-5378.2011.00889.x.","journal-title":"Helicobacter"},{"key":"487_CR4","doi-asserted-by":"publisher","first-page":"15491","DOI":"10.1038\/s41598-017-15490-7","volume":"7","author":"C Wang","year":"2017","unstructured":"Wang C, Nishiyama T, Kikuchi S, et al. Changing trends in the prevalence of H. pylori infection in Japan (1908\u20132003): a systematic review and meta-regression analysis of 170,752 individuals. Sci Rep. 2017;7:15491. https:\/\/doi.org\/10.1038\/s41598-017-15490-7.","journal-title":"Sci Rep"},{"issue":"1","key":"487_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00535-013-0897-8","volume":"49","author":"M Asaka","year":"2014","unstructured":"Asaka M, Kato M, Sakamoto N. Roadmap to eliminate gastric cancer with Helicobacter pylori eradication and consecutive surveillance in Japan. J Gastroenterol. 2014;49(1):1\u20138. https:\/\/doi.org\/10.1007\/s00535-013-0897-8.","journal-title":"J Gastroenterol"},{"key":"487_CR6","doi-asserted-by":"publisher","first-page":"e12837","DOI":"10.1111\/hel.12837","volume":"26","author":"A Kowada","year":"2021","unstructured":"Kowada A, Asaka M. Economic and health impacts of introducing Helicobacter pylori eradication strategy into national gastric cancer policy in Japan: a cost-effectiveness analysis. Helicobacter. 2021;26:e12837. https:\/\/doi.org\/10.1111\/hel.12837.","journal-title":"Helicobacter"},{"issue":"4","key":"487_CR7","doi-asserted-by":"publisher","first-page":"e13120","DOI":"10.1111\/hel.13120","volume":"29","author":"A Kowada","year":"2024","unstructured":"Kowada A. Cost-Effectiveness of Population-Based Helicobacter pylori Screening With Eradication for Optimal Age of Implementation. Helicobacter. 2024;29(4):e13120. https:\/\/doi.org\/10.1111\/hel.13120.","journal-title":"Helicobacter"},{"key":"487_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/oso\/9780198545996.001.0001","volume-title":"Infectious Diseases of Humans: Dynamics and Control","author":"RM Anderson","year":"1991","unstructured":"Anderson RM, May RM. Infectious Diseases of Humans: Dynamics and Control. Oxford: Oxford University Press; 1991."},{"issue":"4","key":"487_CR9","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/sim.4780060405","volume":"6","author":"D Clayton","year":"1987","unstructured":"Clayton D, Schifflers E. Models for temporal variation in cancer rates. I: Age\u2013period\u2013cohort models. Stat Med. 1987;6(4):449\u201367.","journal-title":"Stat Med"},{"issue":"5","key":"487_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1377\/hlthaff.20.5.11","volume":"20","author":"DM Cutler","year":"2001","unstructured":"Cutler DM, McClellan M. Is technological change in medicine worth it? Health Aff (Millwood). 2001;20(5):11\u201329.","journal-title":"Health Aff (Millwood)"},{"key":"487_CR11","volume-title":"Modern Epidemiology","author":"KJ Rothman","year":"2008","unstructured":"Rothman KJ, Greenland S, Lash TL. Modern Epidemiology. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2008.","edition":"3"},{"key":"487_CR12","volume-title":"Causal Inference: What If","author":"MA Hern\u00e1n","year":"2020","unstructured":"Hern\u00e1n MA, Robins JM. Causal Inference: What If. Boca Raton: Chapman & Hall\/CRC; 2020."},{"key":"487_CR13","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/j.1539-6924.2008.01179.x","volume":"29","author":"SH Moolgavkar","year":"2009","unstructured":"Moolgavkar SH, Holford TR, Levy DT, et al. Impact of reduced tobacco smoking on lung cancer mortality in the United States during 1975\u20132000. Risk Anal. 2009;29:483\u201397. https:\/\/doi.org\/10.1111\/j.1539-6924.2008.01179.x.","journal-title":"Risk Anal"},{"key":"487_CR14","unstructured":"Ministry of Health. Labour and Welfare, Japan. Vital statistics. Available at: https:\/\/www.mhlw.go.jp\/english\/database\/db-hw\/vs01.html. Accessed January 30, 2026."},{"issue":"7","key":"487_CR15","doi-asserted-by":"publisher","first-page":"e015855","DOI":"10.1136\/bmjopen-2017-015855","volume":"7","author":"S Hiroi","year":"2017","unstructured":"Hiroi S, Sugano K, Tanaka S, Kawakami K. Impact of health insurance coverage for Helicobacter pylori gastritis on the trends in eradication therapy in Japan: retrospective observational study and simulation study based on real-world data. BMJ Open. 2017;7(7):e015855. https:\/\/doi.org\/10.1136\/bmjopen-2017-015855","journal-title":"BMJ Open"},{"key":"487_CR16","unstructured":"Ministry of Health, Labour and Welfare. Prefectural cancer screening rate 2022. National life foundation survey. Available at: https:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/k-tyosa\/k-tyosa22\/index.html. Accessed January 30, 2026."},{"key":"487_CR17","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1002\/ijc.28065","volume":"133","author":"C Hamashima","year":"2013","unstructured":"Hamashima C, Okamoto M, Shabana M, et al. Sensitivity of endoscopic screening for gastric cancer by the incidence method. Int J Cancer. 2013;133:653\u20139. https:\/\/doi.org\/10.1002\/ijc.28065.","journal-title":"Int J Cancer"},{"key":"487_CR18","doi-asserted-by":"publisher","first-page":"175628481985851","DOI":"10.1177\/1756284819858511","volume":"12","author":"H Mori","year":"2019","unstructured":"Mori H, Suzuki H, Omata F, et al. Current status of first- and second-line Helicobacter pylori eradication therapy in the metropolitan area: a multicenter study with a large number of patients. Ther Adv Gastroenterol. 2019;12:1756284819858511. https:\/\/doi.org\/10.1177\/1756284819858511.","journal-title":"Ther Adv Gastroenterol"},{"key":"487_CR19","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1136\/gutjnl-2020-320839","volume":"69","author":"AC Ford","year":"2020","unstructured":"Ford AC, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis. Gut. 2020;69:2113\u201321. https:\/\/doi.org\/10.1136\/gutjnl-2020-320839.","journal-title":"Gut"},{"key":"487_CR20","unstructured":"National Cancer Center Japan. Cancer statistics in Japan 2025. Foundation for Promotion of Cancer Research. 2025. Available at: https:\/\/ganjoho.jp\/public\/qa_links\/report\/statistics\/2025_en.html. Accessed January 30, 2026."},{"key":"487_CR21","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1007\/s00432-020-03268-w","volume":"146","author":"L Cheng","year":"2020","unstructured":"Cheng L, Chen S, Wu W, Zhuang Q, et al. Gastric cancer in young patients: a separate entity with aggressive features and poor prognosis. J Cancer Res Clin Oncol. 2020;146:2937\u201347. https:\/\/doi.org\/10.1007\/s00432-020-03268-w. .","journal-title":"J Cancer Res Clin Oncol"},{"key":"487_CR22","doi-asserted-by":"publisher","first-page":"472","DOI":"10.7150\/jca.27517","volume":"10","author":"WL Guan","year":"2019","unstructured":"Guan WL, Yuan LP, Yan XL, et al. More attention should be paid to adult gastric cancer patients younger than 35 years old: extremely poor prognosis was found. J Cancer. 2019;10:472\u20138. https:\/\/doi.org\/10.7150\/jca.27517.","journal-title":"J Cancer"},{"issue":"1","key":"487_CR23","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1093\/ije\/dyw098","volume":"46","author":"JL Bernal","year":"2017","unstructured":"Bernal JL, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of public health interventions. Int J Epidemiol. 2017;46(1):348\u201355. https:\/\/doi.org\/10.1093\/ije\/dyw098.","journal-title":"Int J Epidemiol"}],"container-title":["Population Health Metrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12963-026-00487-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12963-026-00487-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12963-026-00487-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T12:03:41Z","timestamp":1780661021000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12963-026-00487-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["487"],"URL":"https:\/\/doi.org\/10.1186\/s12963-026-00487-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8750837\/v1","asserted-by":"object"}]},"ISSN":["1478-7954"],"issn-type":[{"value":"1478-7954","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"assertion":[{"value":"31 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study used publicly available, aggregated national statistics and did not involve human subjects; therefore, ethical approval was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41"}}